If you purchased or otherwise acquired Ardent securities during the Class Period, you may move the Court no later than March 9, 2026 to request appointment as lead plaintiff in this putative class action lawsuit. LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Ardent Health, Inc. ("Ardent†or the "Company†) (NYSE: ARDT) s ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ardent Health, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's accounts receivable and professional malpractice liability insurance [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the March 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Ardent [4]. - The complaint alleges that Ardent and its executives made false statements and failed to disclose critical information regarding the company's financials [6]. - Investors who suffered losses from purchasing Ardent securities between July 18, 2024, and November 12, 2025, are encouraged to contact the firm for legal options [1][4]. Group 2: Financial Impact and Stock Performance - On November 12, 2025, Ardent announced a $43 million reduction in revenue and a $54 million increase in professional liability reserves due to accounting changes [6]. - Following this announcement, Ardent's stock price fell by $4.75 per share, or 33.81%, closing at $9.30 per share on November 13, 2025 [7]. Group 3: Additional Information and Contact - Faruqi & Faruqi encourages anyone with information regarding Ardent's conduct, including whistleblowers and former employees, to reach out [9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - A securities class action lawsuit has been filed against Ardent Health, Inc. following significant adverse accounting adjustments of approximately $90 million, leading to a stock price decline of over 33% [1][7] Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired Ardent securities between July 18, 2024, and November 12, 2025 [1] - The case is titled Postiwala v. Ardent Health, Inc. et al., and focuses on Ardent's disclosures regarding accounts receivable collectability and reserves [3] - The lead plaintiff deadline for the lawsuit is set for March 9, 2026 [2] Group 2: Allegations and Financial Impact - Allegations include that Ardent's leadership was aware of material weaknesses in internal controls related to revenue recognition and failed to disclose these issues [2] - The company reported a revenue decrease of $42.6 million due to a change in accounting estimates and a new revenue accounting system that recognizes reserves earlier [6] - An increase in total operating expenses as a percentage of total revenue was driven by a $47.2 million increase in professional liability reserves [6] Group 3: Market Reaction - Following the financial disclosures on November 12, 2025, Ardent's stock price fell by $4.75, representing a 33% decline [7] - The significant revenue reduction and reserve increase raised questions about whether these issues should have been disclosed to investors earlier [8]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Performance Impact - On November 12, 2025, Ardent Health announced a $43 million decrease in revenue for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for alleged misrepresentations regarding its accounts receivable during the Class Period from July 18, 2024, to November 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ardent Health made false statements about its accounts receivable management, including the reliance on "detailed reviews of historical collections" and the adequacy of its professional malpractice liability insurance [5]. - It is alleged that Ardent Health did not accurately assess the collectability of its accounts receivable, using a 180-day cliff method that inflated reported amounts and delayed loss recognition [5]. - The lawsuit indicates that when issues with claim denials arose, Ardent Health downplayed the situation and failed to write off uncollectible accounts, leading to investor damages when the truth was revealed [5]. Group 2: Class Action Participation - Investors who purchased Ardent Health securities during the Class Period may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by March 9, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ardent Health, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's accounts receivable and professional malpractice liability insurance [2][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Ardent between July 18, 2024, and November 12, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Ardent, with a deadline of March 9, 2026, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Ardent and its executives made false statements and failed to disclose critical information regarding the company's financials [5]. Group 2: Financial Impact and Stock Performance - On November 12, 2025, Ardent reported a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves [5]. - Following this announcement, Ardent's stock price fell by $4.75 per share, or 33.81%, closing at $9.30 per share on November 13, 2025 [6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Ardent's conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections," while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruzannounces that a class action lawsuit has been filed on behalf of shareholders who purchased Ardent Health, Inc. ("Ardent†or the "Company†) (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the "Class Period†). Ardent investors have until March 9, 2026 to file a lead plaintiff motion. Law Offices of Frank R. Cruz Encourages Ardent Health, Inc. (ARDT) Shareholders To Inquire About Securities Fraud Class Action Sha ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly making materially false statements and failing to disclose adverse information regarding its business and financial practices during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025 [1]. - Investors have until March 9, 2026, to seek appointment as lead plaintiff in the class action [2]. Group 2: Allegations Against Ardent Health - The complaint alleges that Ardent Health and its executives misrepresented the company's reliance on historical collection reviews, which were claimed to be a primary source of information for determining collectability [4]. - In reality, the company allegedly used a 180-day threshold for accounts to become fully reserved, leading to inflated accounts receivable balances and delayed recognition of losses [5]. Group 3: Financial Impact - On November 12, 2025, Ardent Health disclosed a $43 million reduction in quarterly revenue and a $54 million increase in professional liability reserves, which were attributed to adverse prior-period claim developments [6]. - Following these disclosures, Ardent Health's stock price fell approximately 33%, from $14.05 to $9.30 per share, resulting in significant losses for investors [7].

New York, New York--(Newsfile Corp. - January 12, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-heal ...